Accès ouvert
2026
supplementary-materials
OpenAlex
Chunyan Lan, Peidong Zhang, Jing Zhao, Qiaqia Li et autres
Supplementary Figure S8 shows re-analysis of an external single-cell dataset validating immune remodeling patterns associated with response to PD-1 plus lenvatinib treatment.
Accès ouvert
2026
supplementary-materials
OpenAlex
Chunyan Lan, Peidong Zhang, Jing Zhao, Qiaqia Li et autres
Supplementary Figure S12 defines the molecular and cellular composition of T cell–myeloid dyad cells in peripheral blood and tumor tissues using single-cell transcriptomic analyses.
Accès ouvert
2026
supplementary-materials
OpenAlex
Chunyan Lan, Peidong Zhang, Jing Zhao, Qiaqia Li et autres
Supplementary Figure S3 summarizes immune cell composition and proportional changes in peripheral blood, based on single-cell RNA sequencing across response groups and treatment time points.
Accès ouvert
2026
supplementary-materials
OpenAlex
Chunyan Lan, Peidong Zhang, Jing Zhao, Qiaqia Li et autres
Supplementary table S3 includes treatment-related adverse events in the total treated patients
Accès ouvert
2026
other
OpenAlex
Chunyan Lan, Peidong Zhang, Jing Zhao, Qiaqia Li et autres
Abstract Although immune checkpoint inhibitors (ICI) show durable responses in various cancers, relapse remains common. The efficacy of retreatment with ICIs is controversial. We conducted a multicenter, single-arm, phase II trial (NCT05824468), including 30 patients with advanced cervical cancer who experienced disease …
Accès ouvert
2026
supplementary-materials
OpenAlex
Chunyan Lan, Peidong Zhang, Jing Zhao, Qiaqia Li et autres
Supplementary table S1 provides a summary of patient baseline clinical characteristics
Accès ouvert
2026
supplementary-materials
OpenAlex
Chunyan Lan, Peidong Zhang, Jing Zhao, Qiaqia Li et autres
Supplementary Figure S10 presents single-cell transcriptomic profiling of immune populations in a murine model treated with PD-1 monotherapy, lenvatinib monotherapy, or combination rechallenge.
Accès ouvert
2026
supplementary-materials
OpenAlex
Chunyan Lan, Peidong Zhang, Jing Zhao, Qiaqia Li et autres
Supplementary table S2 describes detailed clinical information for individual patients
Accès ouvert
2026
supplementary-materials
OpenAlex
Chunyan Lan, Peidong Zhang, Jing Zhao, Qiaqia Li et autres
Supplementary Figure S6 details tumor-infiltrating T cell phenotypes, functional pathway enrichment, and TCR clonotype relationships between circulating and tumor-resident T cell populations.
Accès ouvert
2026
supplementary-materials
OpenAlex
Chunyan Lan, Peidong Zhang, Jing Zhao, Qiaqia Li et autres
Supplementary Figure S5 characterizes the evolution of peripheral T cell states, including subset composition, differentiation trajectories, clonality, and functional scores before and after immune rechallenge.
Accès ouvert
2026
supplementary-materials
OpenAlex
Chunyan Lan, Peidong Zhang, Jing Zhao, Qiaqia Li et autres
Supplementary Figure S9 provides immunofluorescence validation of immune cell depletion efficiency in the murine rechallenge model following anti-CD4, anti-CD8, or anti-CSF1R treatment.
Accès ouvert
2026
supplementary-materials
OpenAlex
Chunyan Lan, Peidong Zhang, Jing Zhao, Qiaqia Li et autres
Supplementary Figure S2 presents genomic correlates of response to immune rechallenge, including mutation landscapes, tumor mutational burden comparisons, and survival analyses stratified by TMB status.